NDA 213690 · Journey
Zilxi
Minocycline Hydrochloride · Topical
Last checked: Nov 20, 2026Latest source record: Feb 20, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2020
May 28, 2020
Approved uses
1
Original approval plus efficacy supplements
Registered trials
291
55 Phase 3, 18 recruiting
FAERS reports
11,615
8,929 serious, 1,645 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Feb 9, 2024.
ZILXI is indicated for the treatment of inflammatory lesions of rosacea in adults [see Clinical Studies ( 14 )] . Limitations of Use This formulation of minocycline has not been evaluated in the treatment of infections. To reduce the development of drug-resistant bacteria as well as to maintain the effectiveness of other antibacterial drugs, ZILXI should be used only as indicated [see Warnings and Precautions ( 5.14 )] . ZILXI is a tetracycline-class drug indicated for the treatment of inflammatory lesions of rosacea in adults. ( 1 ) Limitations of Use This formulation of minocycline has not been evaluated in the treatment of infections. To reduce the development of drug-resistant bacteria as well as to maintain the effectiveness of other antibacterial drugs, ZILXI should be used only as indicated ( 1 ).
Mechanism: The mechanism of action of ZILXI for the treatment of inflammatory lesions of rosacea is unknown.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- ZILXI · MINOCYCLINE HYDROCHLORIDE EQ 1.5% BASE · AEROSOL, FOAM, TOPICAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Minocycline" as an intervention, any sponsor and status, largest first.
- Efficacy and Safety of Minocycline in Patients With Moderate to Severe Acute Ischemic StrokePivotal-lookingCompleted
Beijing Tiantan HospitalAcademic, hospital or other
NCT05836740 · 1,724 participants · Start May 19, 2023 · Primary completion May 20, 2024
Drug: Minocycline hydrochloride capsule; Placebo capsules of Minocycline hydrochloride capsules · For: Ischemic Stroke, Acute
Sites: Beijing, China; Chongqing, China; Shenzhen, China · 58 sites in all
- A Study to Evaluate the Efficacy and Safety of Topical Administration of FMX101 in the Treatment of Moderate-to-Severe Acne VulgarisPivotal-lookingCompleted
Vyne Therapeutics Inc.Industry
NCT03271021 · 1,488 participants · Start Jul 17, 2017 · Primary completion Sep 4, 2018
Drug: FMX101; Vehicle Foam · For: Acne Vulgaris
Sites: Phoenix, Arizona; Tucson, Arizona; Bryant, Arkansas · 98 sites in all
- Efficacy and Safety of Minocycline in the Treatment of Intracerebral HemorrhagePivotal-lookingNot yet recruiting
The First Hospital of Jilin UniversityAcademic, hospital or other
NCT07305896 · 1,248 participants (planned) · Start Dec 31, 2025 · Primary completion Dec 31, 2028
Drug: Minocycline · For: Intracerebral Hemorrhage
- Efficacy and Safety of Minocycline in Acute Spontaneous Intracerebral HemorrhagePivotal-lookingRecruiting
Beijing Tiantan HospitalAcademic, hospital or other
NCT07338175 · 1,192 participants (planned) · Start Apr 2, 2026 · Primary completion Jun 2028
Drug: Minocycline hydrochloride capsules; Placebo capsules of Minocycline hydrochloride capsules · For: Intracerebral Hemorrhage
Sites: Beijing, China; Chongqing, China; Guangzhou, China · 41 sites in all
- Minocycline in Stroke Study at MaimonidesPivotal-lookingRecruiting
Joyce ChenAcademic, hospital or other
NCT07237048 · 1,164 participants (planned) · Start Feb 2, 2026 · Primary completion Dec 1, 2028
Drug: Minocycline 200mg · For: Stroke; Ischemia Stroke; Hemorrhagic Strokes and 4 more
Sites: Brooklyn, New York
- Efficacy and Safety of Minocycline in Patients With Acute Ischaemic Stroke Receiving Intravenous ThrombolysisPivotal-lookingRecruiting
Beijing Tiantan HospitalAcademic, hospital or other
NCT07526987 · 934 participants (planned) · Start Jun 5, 2026 · Primary completion Dec 31, 2028
Drug: Minocycline Hydrochloride Capsule (50 mg per capsule); Placebo of Minocycline Hydrochloride Capsule (50 mg per capsule, containing 0 mg of minocycline) · For: Ischaemic Stroke
Sites: Liaocheng, China; Beijing, China · 3 sites in all
- Minocycline After Successful Endovascular Thrombectomy Recanalization in Acute Anterior Circulation Large Vessel Occlusion (ATTRACTION-MINOA)Pivotal-lookingRecruiting
Xiang LuoAcademic, hospital or other
NCT07594314 · 860 participants (planned) · Start May 21, 2026 · Primary completion Dec 2028
Drug: Minocycline hydrochloride capsule; Placebo capsules of Minocycline hydrochloride capsules · For: Acute Ischemic Stroke; Vessel Occlusion; Endovascular Thrombectomy and 2 more
Sites: Wuhan, China
- Efficacy and Safety of Minocycline Add-on in Patients With NeurosyphilisPivotal-lookingNot yet recruiting
Beijing Ditan HospitalAcademic, hospital or other
NCT07904533 · 778 participants (planned) · Start Nov 15, 2026 · Primary completion May 22, 2028
Drug: Minocycline; Minocycline placebo and 1 more · For: Neurosyphilis
Sites: Beijing, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective1,974
- off label use1,482
- nausea1,075
- pain1,019
- arthralgia1,001
- fatigue957
- drug intolerance913
- rash909
- drug hypersensitivity908
- rheumatoid arthritis879
- joint swelling873
- headache802
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 11 |
| 2005 | 52 |
| 2006 | 7 |
| 2007 | 2 |
| 2008 | 6 |
| 2009 | 79 |
| 2010 | 86 |
| 2011 | 99 |
| 2012 | 233 |
| 2013 | 416 |
| 2014 | 431 |
| 2015 | 539 |
| 2016 | 806 |
| 2017 | 871 |
| 2018 | 894 |
| 2019 | 1,143 |
| 2020 | 1,001 |
| 2021 | 762 |
| 2022 | 695 |
| 2023 | 877 |
| 2024 | 1,202 |
| 2025 | 966 |
| 2026 | 437 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Zilxi (Minocycline HCl)
2024 spending
$430K
Beneficiaries
462
901 claims
Per beneficiary
$931
$15.50 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $21,424 |
| 2021 | $325,070 |
| 2022 | $371,793 |
| 2023 | $402,571 |
| 2024 | $430,122 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Minocycline.
Allen JC · Ann Intern Med 1976 · Clinical Trial, Comparative Study
- Relative effectiveness of antidepressant treatments in treatment-resistant depression: a systematic review and network meta-analysis of randomized controlled trials.
Saelens J, Gramser A, Watzal V, et al. · Neuropsychopharmacology 2025 · Systematic Review, Network Meta-Analysis
- Global status of antimicrobial resistance in clinical Enterococcus faecalis isolates: systematic review and meta-analysis.
Guan L, Beig M, Wang L, et al. · Ann Clin Microbiol Antimicrob 2024 · Systematic Review, Meta-Analysis
- Efficacy and safety of minocycline in patients with acute ischaemic stroke (EMPHASIS): a multicentre, double-blind, randomised controlled trial.
Lu Y, Guan L, Wu J, et al. · Lancet 2026 · Clinical Trial, Phase III, Multicenter Study
- Efficacy of Widely Used Topical Drugs for Rosacea: A Systematic Review and Meta-Analysis.
Gao X, Xiang W · Actas Dermosifiliogr 2025 · Systematic Review, Meta-Analysis
- Interventions for rosacea based on the phenotype approach: an updated systematic review including GRADE assessments.
van Zuuren EJ, Fedorowicz Z, Tan J, et al. · Br J Dermatol 2019 · Systematic Review
Sponsor: Journey
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.